Yasmine Ould-Amer

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Rather than a Janus Kinase 2 inhibitor (ruxolitinib), a specific thrombopoietin receptor (TpoR) inhibitor would be more specific for the treatment of myeloproliferative neoplasms due to TpoR mutations. OBJECTIVE A cell-based phenotypic approach to identify specific TpoR inhibitors was implemented and a library of 505,483 small molecules was(More)
  • 1